読み込み中
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
前日終値
$2.94
−$0.17 · -5.47%
日中の時刻はETです。市場データは遅延する場合があります。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日中レンジ
現在 $2.94
52週レンジ
現在 $2.94
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
52
まちまち
リスク
63
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
日中レンジ
現在 $2.94
52週レンジ
現在 $2.94
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 276.32万 USD | 608.34万 USD | 385.92万 USD | 691.08万 USD | 632.81万 USD |
| 販売・一般管理 | 1200.85万 USD | 931.01万 USD | 1320.46万 USD | 1598.14万 USD | 2337万 USD |
| 営業費用 | 1530.24万 USD | 1613.63万 USD | 2378.95万 USD | 2742.96万 USD | 3374.37万 USD |
| 受取利息 | 23.61万 USD | 57.29万 USD | 78.64万 USD | 36.77万 USD | 1292 USD |
| 支払利息 | 61.86万 USD | 4.76万 USD | 299 USD | 4.88万 USD | 6.94万 USD |
| 減価償却費と償却費 | 54.58万 USD | 49.06万 USD | 250.63万 USD | 453.46万 USD | 404.55万 USD |
| 営業利益 | −1530.24万 USD | −1613.63万 USD | −2378.95万 USD | −2742.96万 USD | −3374.37万 USD |
| 純利益 | −2617.53万 USD | −1420.27万 USD | −1790.22万 USD | −2360.68万 USD | −3528.54万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2024年8月15日 | 1:65 | — | — |
株式分割 | 2019年10月16日 | 1:201 | — | — |
発効済み 2024年8月15日
1:65
発効済み 2019年10月16日
1:201
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
